Porto, December 28, 2020 – Beta Capital, a venture capital firm focused on tech-based early-stage start-ups, launched a new EUR 10m venture capital fund to reinforce its vision of creating a global innovation ecosystem from Portugal.
Managed by Beta Capital, the Fund is backed by firms from different industries and targets EUR 10 million capital, being now open for new capital subscriptions. The participation of portuguese firms may be eligible for tax benefits under the SIFIDE programme.
The Fund’s primary investment focus are tech-based start-ups in the areas of ICT, Lifesciences, Industry 5.0 and Food tech, where the team and the partners have an important and solid experience and track record as investors.
The Fund is expected to invest tickets between EUR 250k to EUR 1m in 10 to 15 promising start-ups.
Just after the exit at Heartgenetics, Beta Capital’s team is excited to focus on growing its active portfolio which includes Boavista Windows, , Bullet Solutions, Matera and Stemmatters.
With experience scaling companies from concept to over 10 million in annual revenue, Beta Capital’s team is eager to find the greatest team of founders with the most promising technologies solving global market needs.
“The launch of Beta Innovation Fund marks another landmark for Beta Capital as a reference investor empowering innovation in Portugal. The best innovators and entrepreneurs may count on us to be their investment partners.” said Roberto Branco, Founder and CEO of Beta Capital.
About Beta Capital
Beta Capital is one of the oldest independent and private VC firms in Portugal, operating since 2003. Focused on supporting innovative tech ventures to unlock its potential by providing smart funding with an hands-on approach, Beta Capital’s team has an entrepreneurial track record and thorough experience in the VC industry, financing innovative businesses. Beta Capital cares about the planet, the Humankind and its stakeholders according to the Principles of Responsible Investment.
Investor Relations Contact